Product Information

DEFERASIROX 360 MG TABLET is a generic product labeled by Zydus Pharmaceuticals (USA) Inc., priced at $1.0484 per EA under NDC 70710127703. Its NADAC has been published 236 times since Apr 20, 2022.

FDA first approved this application on Nov 20, 2019. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

DEFERASIROX 360 MG TABLET

deferasirox
$1.0484per EA

Strength

360 mg/1

NDC

70710127703

Classification

Generic

Dosage Form

TABLET, FILM COATED

Route

ORAL

Effective Date

11/18/2026

Active Ingredients

DEFERASIROX

Approval Type

Generic (ANDA)

FDA Application

ANDA211383

FDA Approved

11/20/2019

TE Code

AB

On Market Since

11/21/2019

Pharmacological Classes

Cytochrome P450 1A2 Inhibitors
Cytochrome P450 2C8 Inhibitors
Cytochrome P450 3A4 Inducers
Iron Chelating Activity
Iron Chelator

Price Statistics

The NADAC for DEFERASIROX 360 MG TABLET has been published 236 times since Apr 20, 2022, and over the history we have for it it has declined 50.2%. The table below summarizes its recorded NADAC range and movement.

Current price$1.0484 per EA
All-time high$2.1034 (Apr 12, 2023)
All-time low$1.0484 (Nov 18, 2026)
52-week high$1.6434
52-week low$1.0484
Median price$1.9490
Average price$1.7457
Largest weekly change+29.6% (Mar 18, 2026)
Weeks tracked236
Tracking sinceApr 20, 2022

Price History

1W

-6.3%

1M

-16.0%

3M

-21.8%

6M

-32.1%

1Y

-14.4%

3Y

-46.7%

5Y

N/A

All

-50.2%

Generic Alternatives

No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the deferasirox market page.

Lowest-Cost Alternatives

No alternatives available

No alternatives found with the same active ingredient and strength in a comparable dosage form.

Continue researching this drug

Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.

Frequently asked questions

What is the NADAC price of DEFERASIROX 360 MG TABLET?

The current National Average Drug Acquisition Cost (NADAC) for DEFERASIROX 360 MG TABLET, manufactured by Zydus Pharmaceuticals (USA) Inc., is $1.0484 per EA (NDC 70710127703), effective Nov 18, 2026.

How has the price of DEFERASIROX 360 MG TABLET changed over time?

Over the history we have for it, the NADAC for DEFERASIROX 360 MG TABLET has declined 50.2%. It has been tracked across 236 weekly CMS publications since Apr 20, 2022.

What are the highest and lowest recorded NADAC prices for DEFERASIROX 360 MG TABLET?

Since Apr 20, 2022, the NADAC for DEFERASIROX 360 MG TABLET has ranged from a low of $1.0484 (Nov 18, 2026) to a high of $2.1034 (Apr 12, 2023), with a median of $1.9490 per EA.

Are there cheaper alternatives to DEFERASIROX 360 MG TABLET?

No other NADAC-published product currently shares the active ingredient and strength of DEFERASIROX 360 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.

Who manufactures DEFERASIROX 360 MG TABLET?

DEFERASIROX 360 MG TABLET (NDC 70710127703) is labeled by Zydus Pharmaceuticals (USA) Inc., and CMS classifies it as a generic product.